PTPI · Petros Pharmaceuticals, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Because the Company does not have sufficient resources to fund its operations for the next twelve months from the date of this filing, management has substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | — | $5.11M | $5.82M | $5.99M | $7.81M | $9.56M | |
| $192.41K | $256.93K | $371.77K | $515.31K | $14.19K | — | — | |
| — | — | $1.21M | $1.63M | $2.29M | $1.6M | $4.05M | |
| — | — | $3.9M | $4.19M | $3.7M | $6.21M | $5.51M | |
| — | — | 76.28% | 71.98% | 61.79% | 79.52% | 57.67% | |
| — | — | $2.62M | $2.41M | $1.74M | $1.79M | $459.64K | |
| $3.4M | $4.64M | $4.63M | $9.26M | $12.21M | $15.59M | $15.67M | |
| — | — | $2.8M | $3.27M | $5.59M | $6.87M | — | |
| — | — | $2.83M | $3.28M | $5.6M | $6.88M | $6.66M | |
| $3.4M | $4.64M | $4.63M | $17.81M | $23.62M | $24.26M | $22.8M | |
| -$3.4M | -$4.64M | -$4.63M | -$13.62M | -$19.92M | -$18.05M | -$17.28M | |
| — | — | -90.51% | -233.88% | -332.37% | -231.05% | -180.78% | |
| — | — | -$1.8M | -$10.33M | -$14.32M | -$11.17M | -$10.62M | |
| — | — | $371.77K | $515.31K | $14.19K | — | — | |
| $196.01K | $141.31K | $3.92M | $5.45M | -$121.82K | — | — | |
| -$3.2M | -$4.5M | -$705.17K | -$8.16M | -$20.04M | -$8.99M | -$22.01M | |
| — | $0 | $0 | $0 | — | $0 | -$1.43M | |
| -$3.2M | $1.91M | -$14.32M | -$8.16M | -$20.04M | -$8.99M | -$20.59M | |
| — | — | -280.1% | -140.2% | -334.4% | -115.05% | -215.35% | |
| — | — | -$26.8M | -$13.81M | -$20.04M | — | — | |
| USD/shares | $8.68 | -$1.56 | -$83.47 | -$158.75 | -$242.00 | -$206.25 | -$962.50 |
| USD/shares | $8.68 | -$1.56 | -$83.47 | -$158.75 | -$242.00 | -$206.25 | -$962.50 |
| shares | — | 28.07M | 321.04K | 87.04K | 82.81K | 43.56K | 21.36K |
| shares | — | 28.07M | 321.04K | 87.04K | 82.81K | 43.56K | 21.36K |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Medical Device Sales | $3,150,752 | $3,536,015 | $3,257,415 | $3,206,221 | $3,201,971 |
| Prescription Medication Sales | $1,961,291 | $2,286,373 | $2,734,639 | $4,605,043 | $6,357,498 |
By Geography (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| United States | $4,042,874 | $4,526,635 | $4,799,132 | $6,572,849 | $8,555,831 |
| Non Us | $1,069,169 | $1,295,753 | $1,192,922 | $1,238,415 | $1,003,638 |